Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiologic measurements

Journal of the Neurological Sciences

Volumn 135, Issue 2, 1996, Pages 114-117

  Russell, James W ^a,b   Karnes, Jeannine L ^a   Dyck, Peter James ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

CMAP; Diabetic neuropathy; Myelinated fiber density; Neurological disability; Sensory detection thresholds; SNAP

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUSCLE ACTION POTENTIAL; MYELINATED NERVE; NERVE BIOPSY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; SURAL NERVE;

EID: 0343930703     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0022-510X(95)00243-U     Document Type: Article

References (23)

1. A consensus report from the Peripheral Nerve Society (1995) Meaningful degree of prevention or stabilization of diabetic polyneuropathy for use in controlled clinical trials. Ann. Neurol., in press.
2. Behse, F., Buchthal, F. and Carlsen, F. (1977) Nerve biopsy and conduction studies in diabetic neuropathy. J. Neurol. Neurosurg. Psychiat., 40: 1072-1082.
3. Buchthal, F. and Rosenfalck, A. (1971) Sensory potentials in polyneuropathy. Brain, 94: 241-262.
4. DCCT Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med., 329: 977-986.
5. Dyck, P.J. (1988) Detection, characterization and staging of polyneuropathy: assessed in diabetics. Muscle Nerve, 11: 21-32.
6. Dyck, P.J. and O'Brien, P.C. (1989) Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care, 12: 649-652.
7. Dyck, P.J., Karnes, J.L., Daube, J., O'Brien, P. and Service, F.J. (1985) Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain, 108: 861-880.
8. Dyck, P.J., Lais, A., Karnes, J.L., O'Brien, P. and Rizza, R. (1986) Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann. Neurol., 19: 425-439.
9. Dyck, P.J., Bushek, W., Spring, E.M., Karnes, J.L., Litchy, W.J., O'Brien, P.C. and Service, F.J. (1987) Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care, 10: 432-440.
10. Dyck, P.J., Karnes, J.L., Gillen, D.A., O'Brien, P.C., Zimmerman, I.R. and Johnson, D.M. (1990) Comparison of algorithms of testing for use in automated evaluation of sensation. Neurology, 40: 1607-1613.
11. Dyck, P.J., Kratz, K.M., Lehman, K.A. and Karnes, J.L. (1991) The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias and reproducibility of neuropathic tests. Neurology, 41: 799-807.
12. Dyck, P.J., Kratz, K.M., Karnes, J.L., Litchy, W.J., Klein, R., Pach, J.M., Wilson, D.M., O'Brien, P.C., Melton 3d., L.J. and Service, F.J. (1993a) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology, 43: 817-824.
13. Dyck, P.J., Giannini, C. and Lais, A. (1993b) Pathological alterations of nerves. In: Dyck, P.J., P.K. Thomas, J.W. Griffin, P.A. Low and J.F. Poduslo (Eds.), Peripheral Neuropathy, W.B. Saunders, Philadelphia, PA, vol. 1, pp. 514-595.
14. Dyck, P.J., Litchy, W.J., Lehman, K.A., Hokanson, J.L., Low, P.A. and O'Brien, P.C. (1995) Variables influencing neuropathic endpoints: The Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology, 45: in press.
15. Gjessing, H.J., Matzen, L.E., Faber, O.K. and Froland, A. (1989) Fasting plasma C-peptide, glucagon stimulated plasma C-peptide and urinary C-peptide in relation to clinical type of diabetes. Diabetologia, 32: 305-311.
16. Jamal, G.A. (1994) The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabetic Med., 11: 145-149.
17. Keen, H., Payan, J., Allawi, J., Walker, J., Jamal, G.A., Weir, A.I., Henderson, L.M., Bissessar, E.A., Watkins, P.J., Sampson, M., Gale, E.A.M., Scarpello, J., Boddie, H.G., Hardy, K.J., Thomas, P.K., Misra, P. and Halonen, J.P. (1993) Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care, 16: 8-15.
18. Melton, 3d, L.J., Dyck, P.J., Karnes, J.L., O'Brien, P.C. and Service, F.J. (1993) Non-response bias in studies of diabetic complications: the Rochester Diabetic Neuropathy Study. J. Clin. Epidemiol., 46: 341-348.
19. Sima, A.A. (1992) Structure-function interactions in the therapeutic response of diabetic neuropathy. J. Diabetes Compl., 6: 64-68.
20. Sima, A.A.F., Brown, M.B., Prashar, A., Chakrabarti, S., Laudadio, C. and Greene, D.A. (1992) The reproducibility and sensitivity of sural nerve morphometry in the assessment of diabetic peripheral neuropathy. Diabetologia, 35: 560-569.
21. Sima, A.A.F., Greene, D.A., Brown, M.B., Hohman, T.C., Hicks, D., Graepel, G.J., Bochenek, W.J., Beg, M. and Gonen, B. (1993a) Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. J. Diabetes Compl., 7: 157-169.
22. Sima, A.A., Prashar, A., Nathaniel, V., Bril, V., Werb, M.R. and Greene, D.A. (1993b) Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Diabetes Med., 10: 115-121.
23. Ziegler, D., Mayer, P., Rathmann, W. and Gries, F.A. (1991) One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res. Clin. Pract., 14: 63-73.